Jefferies Financial Group Inc. Invests $988,000 in Solventum Corporation $SOLV

Jefferies Financial Group Inc. acquired a new position in shares of Solventum Corporation (NYSE:SOLV) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 12,474 shares of the company’s stock, valued at approximately $988,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Assetmark Inc. grew its position in shares of Solventum by 21.4% during the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after buying an additional 128 shares in the last quarter. Hilltop National Bank grew its position in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares in the last quarter. Allworth Financial LP grew its position in shares of Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after buying an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after buying an additional 134 shares in the last quarter. Finally, BOKF NA grew its position in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after buying an additional 141 shares in the last quarter.

Solventum Stock Performance

Shares of SOLV opened at $75.98 on Friday. The stock has a 50 day moving average price of $69.41 and a 200 day moving average price of $75.04. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The company has a market capitalization of $13.16 billion, a price-to-earnings ratio of 9.31, a price-to-earnings-growth ratio of 1.17 and a beta of 0.59. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell acquired 1,475 shares of Solventum stock in a transaction on Tuesday, March 10th. The stock was bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the purchase, the director owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on SOLV shares. Rothschild & Co Redburn started coverage on Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective for the company. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. BTIG Research reaffirmed a “buy” rating and issued a $89.00 price target on shares of Solventum in a report on Wednesday, May 6th. KeyCorp upped their price target on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, UBS Group downgraded Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Thursday, May 14th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and an average price target of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.